PharmVar GeneFocus : CYP4F2
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3405 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Pablo Zubiaur und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM) and Instituto de Investigación Sanitari…. Hauptthemen laut MEDLINE: Cytochrome P450 Family 4. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS).
Abstract (Originalsprache)
The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17 . A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM) and Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa (IP), Madrid, Spain.
- Pharmacogenomics and Tumor Biomarkers Group, Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) CSIC/UAM, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras, Valencia, Spain.
- Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
- Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
ORCID-Profile: Pablo Zubiaur, Cristina Rodríguez-Antona, Erin C Boone, Ann K Daly, Evangelia Eirini Tsermpini, Lubna Q Khasawneh, Katrin Sangkuhl, Jorge Duconge, Mariana R Botton, Jessica Savieo, Charity Nofziger, Michelle Whirl-Carrillo, Teri E Klein, Andrea Gaedigk
Förderung
- NHGRI NIH HHS
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS)
- NIGMS NIH HHS
- Österreichische Forschungsförderungsgesellschaft GmbH (FFG)
- Österreichische Forschungsförderungsgesellschaft
Zitieren
APA
Zubiaur, P., Rodríguez-Antona, C., Boone, E. C., Daly, A. K., Tsermpini, E. E., Khasawneh, L. Q., Sangkuhl, K., Duconge, J., Botton, M. R., Savieo, J., Nofziger, C., Whirl-Carrillo, M., Klein, T. E., & Gaedigk, A. (2024). PharmVar GeneFocus : CYP4F2. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3405
Vancouver
Zubiaur P, Rodríguez-Antona C, Boone EC, Daly AK, Tsermpini EE, Khasawneh LQ, et al. PharmVar GeneFocus : CYP4F2. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3405
BibTeX
@article{Zubiaur2024,
author = {Zubiaur, Pablo and Rodríguez-Antona, Cristina and Boone, Erin C and Daly, Ann K and Tsermpini, Evangelia Eirini and Khasawneh, Lubna Q and Sangkuhl, Katrin and Duconge, Jorge and Botton, Mariana R and Savieo, Jessica and Nofziger, Charity and Whirl-Carrillo, Michelle and Klein, Teri E and Gaedigk, Andrea},
title = {PharmVar GeneFocus : CYP4F2},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3405}
}
EUVIMED